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bacKGround
Breast cancer is the most common malignancy in women 
accounting for about one quarter of all female cancers and is 
the leading cause of cancer-related mortality in women.1 On 
average, 57% of breast cancer cases are diagnosed in women 
below the age of 65 years.2 The average 5-year relative survival 
of European women diagnosed with breast cancer in 1999-2007 
was 81.8 (95% confidence interval: 81.6-82.0).2
The risk of breast cancer is highest in affluent westernised 
populations.1 The Western lifestyle, characterised by a high-
caloric diet, rich in animal fat and proteins, together with low 
physical activity, has been shown to be associated with an 
increased risk of breast cancer.3 Women with a higher body mass 
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abstract
Cancer of the breast is the most common malignancy and 
the leading cause of cancer-related mortality in women. 
Over the past 20 years, mortality from breast cancer in Malta 
has shown a steady decline and survival from this disease 
has registered marked improvement, despite the fact that 
incidence continues to increase. Increased awareness as well 
as the development of specialized breast care health services 
have resulted in positive outcomes, with local mortality rates 
approaching that of the EU-15 average. 
Figure 1: Breast cancer incidence rate time trends: 1994-2013.9  
(Annual fluctations in the incidence rate for Malta are often due to small 
numbers and therefore  a linear trend line has been added which depicts the 
general trend in the incidence rate for Malta) 
Breast cancer: Incidence
index are at a higher risk. On the other hand, sustained physical 
activity throughout the life course protects women by about 
20-40%.4 Furthermore, the excessive consumption of alcohol is 
associated with a mild increase in the risk of breast cancer with 
risk increasing linearly with increasing intake.5 
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Also, recent evidence shows a potentially causal relationship 
between smoking and breast cancer, especially if long-term and 
heavy and if started at an early age.6
Other risk factors include a family history of breast cancer in 
first degree relatives, late childbirth, no history of breastfeeding, 
early menarche and late-onset menopause.7 There is a small 
increase in the relative risk in women who used combined oral 
contraception and in those who used hormonal replacement 
therapy.7 
breast cancer epidemioloGy in malta
i. incidence 
The  Malta National Cancer Registry8 reports that during the 
time period 2011-2013, the average annual incidence in Malta 
amounted to 323 cases per year. The average age at diagnosis was 
63.4 years and the age range varied from 17 to 97 years.
In Malta, the incidence rates of breast cancer have been 
steadily increasing over the past 20 years.  Incidence rates for 
Malta are lower than the average of the EU 15 Member State 
countries  (EU member states pre-2004 accession), but higher 
than the average of the European Region countries (53 countries 
under the remit of the WHO Regional Office for Europe) (figure 
1).9 Overall, it is clear that there is a steady upward trend across 
Europe. Of note, it appears that since 2008, the upward trend for 
the average EU 15 Member State countries has plateaued (the 
annual rates show a more flattened pattern).
Figure 2: Breast cancer mortality rate time trends: 1993-20138
Breast cancer: Mortality
ii. mortality
During the time period 2011-2013, the average annual mortality 
attributed to breast cancer in Malta amounted to 82 deaths. The 
average age at death from breast cancer was  71.1 years and the 
age range varied from 31 to 96 years.10
Time trends for the breast cancer mortality rates for 
Malta have shown a steep decrease over the past 20 years, 
approaching the average EU 15 mortality rate. The time trends 
of standardised mortality rates of breast cancer in the European 
Region, the EU 15 member states, and in Malta are depicted in 
Figure 2.9 The fall in standardized mortality rate over time is due 
both to an increase in the age at death and improvements in the 
overall survival from breast cancer.
iii. surViVal
The prognosis of breast cancer depends on the stage at diagnosis, 
the histological type and  tumour grade, the immunophenotype 
(such as the expression of human epidermal growth factor 
receptor type 2 and oestrogen/progesterone receptor), and 
the overall health status of the individual.11 Improvements in 
survival are the product of health care access, earlier disease 
detection (for example, through population screening), and 
advances in treatment. The widespread use of hormonal agents 
in oestrogen receptor-positive tumours, coupled with effective 
chemotherapeutic drug regimes have both resulted in a better 
overall prognsois, including an increase in remission  rates and 
lower recurrence rates.12
In Malta, the 5-year relative survival rate has increased 
from 75.4 years for women diagnosed in 1990-1994,13 to 75.9 
years14 and 84.4 years15 for those diagnosed in 1995-1999 and 
2000-2007, respectively.  Despite this clear improvement in 
breast cancer outcomes, the relative survival rate in Malta is 
still persistently lower than the European average (based on 29 
European countries grouped into five European regions).15 This 
distinction is most discernible when comparing the outcomes 
for Malta with those of Northern Europe but it is also notable 
when compared to the average for Southern Europe (see Table 
1).
In conclusion, over the past 20 years, mortality from breast 
cancer in Malta has shown a steady decline, survival from 
this disease has registered unrelenting improvement, whilst 
incidence continues to increase. Consequently, the national 
healthcare services have grown and evolved in parallel to meet 
the rising and diversifying needs of the Maltese population.
national healthcare serVices for breast cancer
The Breast Care Unit service was established in 2000 and is 
currently housed at Mater Dei Hospital. This Unit caters for 
the relatiVe surViVal rate [of breast cancer] in malta 
is still persistently lower than the european aVeraGe ...
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the diagnosis and surgical treatment of invasive breast cancer 
(just over 300 new cases per year), as well as non-malignant 
breast pathologies. It also offers follow-up services. The cancer 
care pathways (diagnostic workup and treatment plans) of 
women diagnosed with breast cancer are discussed at weekly 
multi-disciplinary team (MDT) meetings. The MDT includes 
breast cancer surgeons and nurses, pathologists, radiologists, 
oncologists and managers from the national screening program. 
The Breast Care Unit was renamed the Agatha Breast Unit in 
2015 during celebrations to mark 15 years since its inception. 
During the celebration program, guidelines for diagnosis, 
treatment and follow-up, coordinated by the clinic’s surgical 
professionals, were presented and launched. New surgical 
techniques such as oncoplastic and immediate reconstruction 
surgery have been introduced to complement the plastic and 
reconstruction surgery that were already available. 
Breast cancer patients are also offered specialized allied 
healthcare professional services such as occupational therapy, 
physiotherapy, as well as the services of clinical psychologists 
and social workers. Physiotherapists also organize a specialized 
lymphoedema clinic. A number of publications offering 
information to clients and patients have also been developed 
and are distributed by the National Screening Unit, the Agatha 
Breast Unit and the Sir Anthony Mamo Oncology Centre. 
Newer health technologies are improving the diagnostic 
capabilities across the board. In the medical imaging 
department, two full-field digital mammography machines with 
Age-standardised relative survival with 95% confi-
dence intervals in parentheses
Number of 
cases 1-year 5-year Conditional
Northern Europe 138,062 96.4 (96.2 - 96.5) 84.7 (84.4 - 85.1) 87.9 (87.6 - 88.3)
Ireland and UK 364,027 93.4 (93.3-93.6) 79.2 (79.0 - 79.4) 84.7 (84.5 - 85.0)
Central Europe 318,766 95.7 (95.6 - 95.8) 83.9 (83.6 - 84.1) 87.7 (87.5 - 87.9)
Southern Europe 173,693 95.6 (95.4 - 95.7) 83.6 (83.3 - 83.9) 87.5 (87.2 - 87.8)
Malta 1,806 95.7 (94.4 - 97.1) 80.8 (77.3 - 84.4) 84.4 (81.0 - 87.9)
Eastern Europe 121,443 91.0 (90.8 - 91.3) 73.7 (73.2 - 74.1) 80.9 (80.5 - 81.4)
Europe (based 
on 29 European 
countries)
1,115,991 94.8 (94.7 - 94.9) 81.8 (81.6 - 82.0) 86.3 (86.1 - 86.5)
Table 1: Age-specific and age-standardised relative survival for breast 
cancers diagnosed in 2000-2007, by European region and overall15
stereo-guided equipment, ultrasound equipment equiped with 
2D and 3D probes, and a 3 Tesla MRI scanner with dedicated 
breast software were introduced. Current pathology services 
are also increasingly relying on  immunohistochemistry to test 
for oestrogen and progesterone receptors, HER2 amplification 
and other basal biomarkers. The results of these investigations 
are allowing a more personalised approach to the adjuvant and 
neo-adjuvant therapy that can be offered to patients. 
Oncological treatments, namely chemotherapy, hormone 
therapy and radiotherapy, and palliative care are managed and 
delivered at Sir Anthony Mamo Oncology Centre. The new 
Oncology Centre, which was inaugurated in 2015, is equiped 
with 3 linear accelerators, planning stations and a large bore 
CT simulator.  
Population-based organised mammography screening was 
introduced towards the end of 2009 for women aged between 
50-60 years. By 2015, this has been extended up to women that 
are 65 years old. In the Health Interview Survey (2008) that was 
conducted before the introduction of the organised screening 
program, 40% of women in the 50-65 year group reported 
that they had at least one mammography in the preceding 
three years.16 During 2013, the screening program performed 
mammography screening on 9,027 women (58.1% of the 
women invited for screening during 2013). Of these, 44 women 
were eventually referred for further investigation and treatment 
of breast pathology. The breast pathology of 35 of these women 
was confirmed to be invasive breast cancer while the remaining 
9 cases were eventually confirmed to be carcinoma-in-situ. 
conclusion
The comprehensive breast cancer care services which 
are offered in Malta, have consistently been shown to be 
continuously improving. The outcomes of these services can 
be further improved through initiatives to lower incidence 
through the promotion of healthier lifestyles, and reduce 
mortality by advancing earlier detection through health 
education and population screening. 
Improvement of the breast care services offered can be 
more vigorously channeled towards achieving higher quality 
of these services such as through the introduction of initiatives 
to help reduce the waiting times between different phases of 
the breast cancer care pathways. Additional effort needs to be 
devoted towards achieving more positive patients’ experience 
during the diagnostic and therapeutic phases as well as beyond, 
through the emerging and important themes of rehabilitation 
and survivorship. The latter two domains are constantly 
growing in importance and significance in tandem with 
achievements in cancer survival. ref
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